Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

Rhea-AI Summary

Alpha Cognition (ACOG) has announced an investor update call scheduled for January 28th, 2025, at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), their FDA-approved treatment for mild-to-moderate Alzheimer's disease. The presentation will focus on addressing the $2 billion U.S. long-term care market.

ZUNVEYL is notably only the second oral Alzheimer's treatment approved in over a decade. The call will feature presentations from the company's leadership team, including CEO Michael McFadden and COO/CCO Lauren D'Angelo, alongside key thought leaders Dr. Hany Mohamed and Cathy Parker, who bring extensive experience in long-term care settings.

The presentation will cover market positioning, launch strategy, and long-term growth objectives for the Q1 2025 commercial launch.

Positive

• FDA approval secured for ZUNVEYL, only the second oral Alzheimer's treatment in over a decade
• Targeting a substantial $2 billion U.S. long-term care market opportunity

Negative

• None.

Insights

Neuroscience Market Analyst

The upcoming launch of ZUNVEYL into the $2 billion U.S. long-term care Alzheimer's market represents a pivotal opportunity. As only the second oral AD treatment approved in over a decade, ZUNVEYL enters a severely underserved market with significant growth potential. The long-term care segment is particularly attractive due to its concentrated patient populations and established reimbursement pathways.

Key market dynamics support a strong commercial launch: the aging population is driving increased demand for AD treatments, while the long-term care setting offers streamlined access to prescribers and patients. The inclusion of experienced geriatric specialists as presenters suggests a well-targeted approach to penetrating this market segment.

However, success will heavily depend on the company's ability to differentiate ZUNVEYL from existing treatments and secure favorable formulary positions. The $88.7M market cap indicates investor skepticism about execution capabilities - successful commercialization could drive significant value creation if the company can capture even a modest share of this market.

Commercial Strategy Expert

The Q1 2025 launch strategy presentation comes at a critical time for Alpha Cognition's commercialization efforts. The focus on the long-term care market demonstrates a smart, targeted approach rather than attempting a broad market launch. This strategy allows for:

• More efficient use of marketing resources
• Faster market penetration through concentrated prescriber bases
• Better control over pricing and reimbursement dynamics

The involvement of key opinion leaders with extensive long-term care experience suggests the company has built important relationships within their target market. However, the relatively small market cap raises questions about the company's commercial infrastructure and financial resources to execute a successful launch. Investors should closely monitor the presentation for details on sales force sizing, marketing budget allocation and payer strategy to assess execution capabilities.

DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on Tuesday, January 28^th, 2025 at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimer’s disease (AD). The call will focus on the company’s plans to address the needs of a growing patient population within the $2 billion long-term care market in the U.S.

Webcast Details
Date: Tuesday, January 28, 2025
Time: 4pm ET
Webcast Registration: Click HERE to register

A live webcast of the presentation will be available via the registration link above. A replay will also be accessible following the event on the Alpha Cognition website at www.alphacognition.com.

ZUNVEYL represents a significant advancement in Alzheimer’s care and it is only the second oral AD treatment to be approved in more than a decade. Alpha Cognition’s leadership team will provide key updates on the Q1 2025 commercial launch strategy, including market positioning, launch strategy, and long-term growth objectives. Additionally, key thought leaders who actively serve AD patients in long-term care will share their perspectives on the product’s potential impact within the evolving treatment landscape.

Presenters will include:

• Michael McFadden, Chief Executive Officer
• Lauren D’Angelo, Chief Operating Officer and Chief Commercial Officer
• Dr. Hany Mohamed, Pharm. D, R. Ph, BCGP, BCMTMS: Dr. Mohamed is a Board-Certified Geriatric Pharmacist (BCGP) with over 20 years of long-term care pharmacy experience.
• Cathy Parker, MS, GNP-BC: Ms. Parker, a board-certified Gerontological Nurse Practitioner, has over 20 years of experience treating patients in long-term care settings.

About ZUNVEYL

ZUNVEYL (benzgalantamine) is a twice-daily treatment designed to address the cognitive symptoms of mild-to-moderate Alzheimer’s disease. By enhancing cholinergic function in the brain, ZUNVEYL supports memory, learning, and overall cognitive function, offering a meaningful improvement for patients and their caregivers.

Targeted for the long-term care market, ZUNVEYL is uniquely positioned to address the needs of a growing patient population in a segment valued at $2 billion annually in the United States. Alpha Cognition is committed to ensuring ZUNVEYL is accessible to patients and caregivers, supported by robust market access strategies and a dedicated commercial team.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

For more information, please visit www.alphacognition.com.

INDICATION

ZUNVEYL (benzgalantamine) is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.

IMPORTANT SAFETY INFORMATION

Contraindications

ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or any inactive ingredients in ZUNVEYL.

Warnings and Precautions

• Serious Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed and alternative therapy should be considered.
• Cardiovascular conditions: Cholinesterase inhibitors, including ZUNVEYL, may have vagotonic effects on the sinoatrial and atrioventricular nodes. These effects may manifest as bradycardia or heart block in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of donepezil.
• Peptic ulcer disease and gastrointestinal bleeding: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs).
• Genitourinary conditions: Although not observed in clinical trials of ZUNVEYL, bladder outflow obstruction may occur.
• Pulmonary conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease. Monitor for respiratory adverse effects.

Adverse Reactions

The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.

Drug Interactions

Cholinesterase inhibitors, including galantamine, have the potential to interfere with the activity of anticholinergic medications. A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol.

These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward-looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements may include statements regarding the January investor update call, the efficacy and tolerability of ZUNVEYL , the long-term benefits of ZUNVEYL, the Company’s timing and planned activities and business strategy to launch ZUNVEYL, the potential timing for the availability of ZUNVEYL, the potential future developments of ZUNVEYL, the market size and demand for ZUNVEYL and the Company’s potential growth opportunities, capital requirements,. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at www.sec.gov. These forward-looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250106259636/en/

Investor Contact:

Alpha Cognition Inc.

Email: ir@alphacognition.com

Media Contact:

Rob Lynch

Email: robert@stonegateinc.com

Phone: 847-867-9202

Source: Alpha Cognition Inc.

FAQ

When is Alpha Cognition (ACOG) launching ZUNVEYL in the U.S. market?

Alpha Cognition plans to launch ZUNVEYL in Q1 2025 in the U.S. market.

What is the market size for ZUNVEYL (ACOG) in the U.S. long-term care segment?

The U.S. long-term care market that ZUNVEYL is targeting represents a $2 billion opportunity.

What type of Alzheimer's patients can be treated with Alpha Cognition's ZUNVEYL?

ZUNVEYL is FDA-approved for treating mild-to-moderate Alzheimer's disease patients.

When is Alpha Cognition's (ACOG) investor update call scheduled for ZUNVEYL launch strategy?

The investor update call is scheduled for Tuesday, January 28th, 2025, at 4pm EST.

How significant is ZUNVEYL's FDA approval in the Alzheimer's treatment landscape?

ZUNVEYL is only the second oral Alzheimer's disease treatment to receive FDA approval in more than a decade.